Unibest

Pipeline Database

UB275

Imipenem and Cilastatin Sodium for Injection

Submit a ProjectNew Drug Candidates DB

UB275

ProductImipenem and Cilastatin Sodium for Injection
Strength0.25g: 0.25g; 0.5g: 0.5g
IndicationsBacterial infection; Mixed infection; Peritonitis; Hepatobiliary infection; Intra-abdominal abscess; Appendicitis; Female genital tract infection; Lower respiratory tract infection; Skin and soft tissue infection; Urinary tract infection; Osteomyelitis; Septic arthritis; Sepsis
TherapeuticsInfectious Diseases
GMPCN - NMPA
RegistrationChina
ModalitiesSmall Molecule

Exclusive Summary

  • - Fully off-patent and widely genericized worldwide, enabling rapid entry via distribution into hospital tenders and shortage backfills
  • - On WHO Essential Medicines List and in AWaRe Watch group; endorsed by IDSA and other guidelines for severe ESBL infections, HAP/VAP, and cIAI
  • - Serves high-burden critical-care needs (≈48.9M sepsis cases and 11M related deaths annually; HAI prevalence 7–10%), with AMR trends sustaining demand
  • - Dual SKUs (0.25/0.25 and 0.5/0.5) support pediatric/renal-adjusted dosing and pharmacy stewardship across departments
  • - Despite crowded competition, 70–90% price discount vs originator plus reliable supply (Zone IVb stability, dedicated β-lactam sterile line, robust CTD) can win tenders in emerging markets

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →